Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses.
Epidemiology
Mendelian randomization
Metabolomics
Sleep
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
received:
06
10
2020
accepted:
11
02
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Sleep traits are associated with cardiometabolic disease risk, with evidence from Mendelian randomization (MR) suggesting that insomnia symptoms and shorter sleep duration increase coronary artery disease risk. We combined adjusted multivariable regression (AMV) and MR analyses of phenotypes of unfavourable sleep on 113 metabolomic traits to investigate possible biochemical mechanisms linking sleep to cardiovascular disease. We used AMV (N = 17,368) combined with two-sample MR (N = 38,618) to examine effects of self-reported insomnia symptoms, total habitual sleep duration, and chronotype on 113 metabolomic traits. The AMV analyses were conducted on data from 10 cohorts of mostly Europeans, adjusted for age, sex, and body mass index. For the MR analyses, we used summary results from published European-ancestry genome-wide association studies of self-reported sleep traits and of nuclear magnetic resonance (NMR) serum metabolites. We used the inverse-variance weighted (IVW) method and complemented this with sensitivity analyses to assess MR assumptions. We found consistent evidence from AMV and MR analyses for associations of usual vs. sometimes/rare/never insomnia symptoms with lower citrate (- 0.08 standard deviation (SD)[95% confidence interval (CI) - 0.12, - 0.03] in AMV and - 0.03SD [- 0.07, - 0.003] in MR), higher glycoprotein acetyls (0.08SD [95% CI 0.03, 0.12] in AMV and 0.06SD [0.03, 0.10) in MR]), lower total very large HDL particles (- 0.04SD [- 0.08, 0.00] in AMV and - 0.05SD [- 0.09, - 0.02] in MR), and lower phospholipids in very large HDL particles (- 0.04SD [- 0.08, 0.002] in AMV and - 0.05SD [- 0.08, - 0.02] in MR). Longer total sleep duration associated with higher creatinine concentrations using both methods (0.02SD per 1 h [0.01, 0.03] in AMV and 0.15SD [0.02, 0.29] in MR) and with isoleucine in MR analyses (0.22SD [0.08, 0.35]). No consistent evidence was observed for effects of chronotype on metabolomic measures. Whilst our results suggested that unfavourable sleep traits may not cause widespread metabolic disruption, some notable effects were observed. The evidence for possible effects of insomnia symptoms on glycoprotein acetyls and citrate and longer total sleep duration on creatinine and isoleucine might explain some of the effects, found in MR analyses of these sleep traits on coronary heart disease, which warrant further investigation.
Sections du résumé
BACKGROUND
Sleep traits are associated with cardiometabolic disease risk, with evidence from Mendelian randomization (MR) suggesting that insomnia symptoms and shorter sleep duration increase coronary artery disease risk. We combined adjusted multivariable regression (AMV) and MR analyses of phenotypes of unfavourable sleep on 113 metabolomic traits to investigate possible biochemical mechanisms linking sleep to cardiovascular disease.
METHODS
We used AMV (N = 17,368) combined with two-sample MR (N = 38,618) to examine effects of self-reported insomnia symptoms, total habitual sleep duration, and chronotype on 113 metabolomic traits. The AMV analyses were conducted on data from 10 cohorts of mostly Europeans, adjusted for age, sex, and body mass index. For the MR analyses, we used summary results from published European-ancestry genome-wide association studies of self-reported sleep traits and of nuclear magnetic resonance (NMR) serum metabolites. We used the inverse-variance weighted (IVW) method and complemented this with sensitivity analyses to assess MR assumptions.
RESULTS
We found consistent evidence from AMV and MR analyses for associations of usual vs. sometimes/rare/never insomnia symptoms with lower citrate (- 0.08 standard deviation (SD)[95% confidence interval (CI) - 0.12, - 0.03] in AMV and - 0.03SD [- 0.07, - 0.003] in MR), higher glycoprotein acetyls (0.08SD [95% CI 0.03, 0.12] in AMV and 0.06SD [0.03, 0.10) in MR]), lower total very large HDL particles (- 0.04SD [- 0.08, 0.00] in AMV and - 0.05SD [- 0.09, - 0.02] in MR), and lower phospholipids in very large HDL particles (- 0.04SD [- 0.08, 0.002] in AMV and - 0.05SD [- 0.08, - 0.02] in MR). Longer total sleep duration associated with higher creatinine concentrations using both methods (0.02SD per 1 h [0.01, 0.03] in AMV and 0.15SD [0.02, 0.29] in MR) and with isoleucine in MR analyses (0.22SD [0.08, 0.35]). No consistent evidence was observed for effects of chronotype on metabolomic measures.
CONCLUSIONS
Whilst our results suggested that unfavourable sleep traits may not cause widespread metabolic disruption, some notable effects were observed. The evidence for possible effects of insomnia symptoms on glycoprotein acetyls and citrate and longer total sleep duration on creatinine and isoleucine might explain some of the effects, found in MR analyses of these sleep traits on coronary heart disease, which warrant further investigation.
Identifiants
pubmed: 33731105
doi: 10.1186/s12916-021-01939-0
pii: 10.1186/s12916-021-01939-0
pmc: PMC7971964
doi:
Substances chimiques
Isoleucine
04Y7590D77
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Subventions
Organisme : British Heart Foundation
ID : AA/18/7/34219
Pays : United Kingdom
Organisme : British Heart Foundation
ID : 17/0005700
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204813/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206046/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/6
Pays : United Kingdom
Organisme : Diabetes UK
ID : 17/0005700
Pays : United Kingdom
Références
Circulation. 2015 Mar 3;131(9):774-85
pubmed: 25573147
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Nat Commun. 2019 Nov 12;10(1):5121
pubmed: 31719535
Circulation. 2018 Nov 27;138(22):2499-2512
pubmed: 30524137
Eur Heart J. 2011 Jun;32(12):1484-92
pubmed: 21300732
Atherosclerosis. 2018 Oct;277:195-203
pubmed: 29910030
BMJ. 2011 Feb 15;342:d548
pubmed: 21325005
Twin Res Hum Genet. 2010 Jun;13(3):231-45
pubmed: 20477721
Stat Med. 2017 May 20;36(11):1783-1802
pubmed: 28114746
Neurology. 2019 Dec 3;93(23):e2110-e2120
pubmed: 31694922
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Nat Commun. 2019 Mar 7;10(1):1100
pubmed: 30846698
Sleep Med Rev. 2019 Dec;48:101215
pubmed: 31630016
Epilepsia. 2004 Nov;45(11):1397-404
pubmed: 15509241
Eur J Epidemiol. 2013 Jun;28(6):513-23
pubmed: 23576214
Sleep. 2013 Nov 01;36(11):1587-95
pubmed: 24179290
Eur J Prev Cardiol. 2014 Jan;21(1):57-64
pubmed: 22942213
Circ Genom Precis Med. 2018 May;11(5):e002034
pubmed: 29728394
Nat Commun. 2016 Nov 28;7:13457
pubmed: 27892461
Am J Cardiol. 1999 Nov 15;84(10):1192-7
pubmed: 10569329
N Engl J Med. 2012 Nov 29;367(22):2089-99
pubmed: 23126252
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10761-6
pubmed: 25002497
Int J Methods Psychiatr Res. 2008;17(3):121-40
pubmed: 18763692
Twin Res Hum Genet. 2013 Feb;16(1):252-67
pubmed: 23186620
Circ Cardiovasc Genet. 2015 Feb;8(1):192-206
pubmed: 25691689
Sleep Med. 2014 Sep;15(9):1115-21
pubmed: 25047172
J Clin Med. 2020 Jan 27;9(2):
pubmed: 32012794
N Engl J Med. 2007 Nov 22;357(21):2109-22
pubmed: 17984165
Front Genet. 2019 May 03;10:415
pubmed: 31130989
Int J Epidemiol. 2016 Jun;45(3):908-15
pubmed: 27427429
J Am Coll Cardiol. 2019 Sep 10;74(10):1304-1314
pubmed: 31488267
Int J Epidemiol. 2016 Dec 1;45(6):1866-1886
pubmed: 28108528
Elife. 2018 May 30;7:
pubmed: 29846171
Chronobiol Int. 2018 Aug;35(8):1045-1053
pubmed: 29642757
Sleep Med Rev. 2018 Jun;39:25-36
pubmed: 28890167
Nat Genet. 2019 Mar;51(3):387-393
pubmed: 30804566
Int J Epidemiol. 2007 Dec;36(6):1196-204
pubmed: 17591638
Nat Genet. 2019 Mar;51(3):394-403
pubmed: 30804565
Sleep. 2018 Jun 1;41(6):
pubmed: 29701831
J Sleep Res. 2019 Aug;28(4):e12776
pubmed: 30324729
Sleep. 2008 May;31(5):645-52
pubmed: 18517035
Eur J Epidemiol. 2017 Sep;32(9):807-850
pubmed: 29064009
Int J Epidemiol. 2018 Feb 1;47(1):21-21g
pubmed: 29040543
PLoS Med. 2017 Aug 22;14(8):e1002376
pubmed: 28829768
Bioinformatics. 2014 Oct;30(19):2811-2
pubmed: 24930139
N Engl J Med. 2019 Mar 14;380(11):1033-1042
pubmed: 30865797
Cephalalgia. 2011 Oct;31(13):1359-67
pubmed: 21914734
Epidemiology. 2014 May;25(3):427-35
pubmed: 24681576
BMJ Open. 2017 Dec 14;7(12):e017873
pubmed: 29247091
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Sleep Med. 2014 Dec;15(12):1456-62
pubmed: 25450058
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
HSOA J Hum Endocrinol. 2016;1(1):
pubmed: 28286881
Lancet. 2010 Jan 9;375(9709):132-40
pubmed: 20031199
Lancet. 2002 Nov 23;360(9346):1623-30
pubmed: 12457784
Psychiatry Res. 2018 Oct;268:354-357
pubmed: 30098543
Lancet. 2012 Aug 11;380(9841):572-80
pubmed: 22607825
Sleep Med Rev. 2014 Aug;18(4):293-7
pubmed: 23890470
Am J Cardiol. 2016 Jun 15;117(12):1928-33
pubmed: 27138185
Nat Commun. 2019 Jan 29;10(1):343
pubmed: 30696823
BMC Public Health. 2013 Apr 27;13:402
pubmed: 23621920
J Transl Med. 2017 Oct 27;15(1):219
pubmed: 29078787
Metabolites. 2020 Apr 23;10(4):
pubmed: 32340170
Nat Commun. 2016 Mar 23;7:11122
pubmed: 27005778
J Med Internet Res. 2013 Nov 06;15(11):e233
pubmed: 24195965
J Am Coll Cardiol. 2019 Jun 25;73(24):3118-3131
pubmed: 31221261
Sleep Med. 2017 Apr;32:246-256
pubmed: 27743803
PLoS Med. 2007 Sep;4(9):e270
pubmed: 17803353
PLoS Med. 2016 Nov 29;13(11):e1002179
pubmed: 27898682